Identifying determinants of varenicline adherence using the Theoretical Domains framework: a rapid review.
Barriers
Behaviour Change Techniques
Facilitators
Medication Adherence
Smoking Cessation
Theoretical Domains Framework
Varenicline
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
04 Mar 2024
04 Mar 2024
Historique:
received:
08
10
2023
accepted:
17
02
2024
medline:
5
3
2024
pubmed:
5
3
2024
entrez:
4
3
2024
Statut:
epublish
Résumé
Adhering to varenicline has been shown to significantly improve the chances of successfully quitting smoking, with studies indicating a twofold increase in 6-month quit rates. However, despite its potential benefits, many individuals struggle with maintaining good adherence to varenicline; thus there is a need to develop scalable strategies to help people adhere. As a first step to inform the development of an intervention to improve adherence to varenicline, we conducted a rapid literature review to identify: 1) modifiable barriers and facilitators to varenicline adherence, and 2) behaviour change techniques associated with increased adherence to varenicline. We searched MEDLINE, Embase, APA PsycINFO, CINAHL, and the Cochrane Central Register of Controlled Trials for relevant studies published between 2006 and 2022. Search terms included "varenicline," "smoking cessation," and "adherence," and their respective subject headings and synonyms. We screened and included studies reporting modifiable determinants of adherence to varenicline and then assessed quality, extracted modifiable determinants and mapped them to the Theoretical Domains Framework version 2 and the Behaviour Change Technique Taxonomy version 1. A total of 1,221 titles were identified through the database searches; 61 met the eligibility criteria. Most of the studies were randomized controlled trials and predominantly focused on barriers to varenicline. Only nine studies explicitly mentioned behaviour change techniques used to help varenicline adherence. Eight domains were identified as barriers to varenicline adherence (behavioural regulation, memory, goals, intentions, beliefs about capabilities, beliefs about consequences, optimism/pessimism, and environmental context) and five as facilitators (knowledge, behavioural regulation, beliefs about capabilities, social influences, and environmental context). This study identifies barriers and facilitators that should be addressed when developing a complex adherence intervention tailored to patients' needs based on modifiable determinants of medication adherence, some of which are under- used by existing adherence interventions. The findings from this review will inform the design of a theory-based healthbot planned to improve varenicline adherence in people undergoing smoking cessation treatment. This study was registered with PROSPERO (# CRD42022321838).
Sections du résumé
BACKGROUND
BACKGROUND
Adhering to varenicline has been shown to significantly improve the chances of successfully quitting smoking, with studies indicating a twofold increase in 6-month quit rates. However, despite its potential benefits, many individuals struggle with maintaining good adherence to varenicline; thus there is a need to develop scalable strategies to help people adhere. As a first step to inform the development of an intervention to improve adherence to varenicline, we conducted a rapid literature review to identify: 1) modifiable barriers and facilitators to varenicline adherence, and 2) behaviour change techniques associated with increased adherence to varenicline.
METHODS
METHODS
We searched MEDLINE, Embase, APA PsycINFO, CINAHL, and the Cochrane Central Register of Controlled Trials for relevant studies published between 2006 and 2022. Search terms included "varenicline," "smoking cessation," and "adherence," and their respective subject headings and synonyms. We screened and included studies reporting modifiable determinants of adherence to varenicline and then assessed quality, extracted modifiable determinants and mapped them to the Theoretical Domains Framework version 2 and the Behaviour Change Technique Taxonomy version 1.
RESULTS
RESULTS
A total of 1,221 titles were identified through the database searches; 61 met the eligibility criteria. Most of the studies were randomized controlled trials and predominantly focused on barriers to varenicline. Only nine studies explicitly mentioned behaviour change techniques used to help varenicline adherence. Eight domains were identified as barriers to varenicline adherence (behavioural regulation, memory, goals, intentions, beliefs about capabilities, beliefs about consequences, optimism/pessimism, and environmental context) and five as facilitators (knowledge, behavioural regulation, beliefs about capabilities, social influences, and environmental context).
CONCLUSIONS
CONCLUSIONS
This study identifies barriers and facilitators that should be addressed when developing a complex adherence intervention tailored to patients' needs based on modifiable determinants of medication adherence, some of which are under- used by existing adherence interventions. The findings from this review will inform the design of a theory-based healthbot planned to improve varenicline adherence in people undergoing smoking cessation treatment.
SYSTEMATIC REVIEW REGISTRATION
BACKGROUND
This study was registered with PROSPERO (# CRD42022321838).
Identifiants
pubmed: 38438884
doi: 10.1186/s12889-024-18139-z
pii: 10.1186/s12889-024-18139-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
679Subventions
Organisme : CIHR
ID : PJT 180405
Pays : Canada
Organisme : CIHR
ID : PJT 180405
Pays : Canada
Organisme : CIHR
ID : PJT 180405
Pays : Canada
Organisme : CIHR
ID : PJT 180405
Pays : Canada
Organisme : CIHR
ID : PJT 180405
Pays : Canada
Informations de copyright
© 2024. The Author(s).
Références
World Health Organization. 2019. Tobacco. Available from: https://www.who.int/news-room/fact-sheets/detail/tobacco Cited 2022 Nov 18
Rigotti NA, Kruse GR, Livingstone-Banks J, Hartmann-Boyce J. Treatment of Tobacco Smoking: A Review. JAMA. 2022;327(6):566–77.
pubmed: 35133411
doi: 10.1001/jama.2022.0395
Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation An overview and network meta-analysis. Cochrane Database Syst Rev. 2013;2013(5):CD009329.
pubmed: 23728690
pmcid: 8406789
Tonstad S, Arons C, Rollema H, Berlin I, Hajek P, Fagerström K, et al. Varenicline: mode of action, efficacy, safety and accumulated experience salient for clinical populations. Curr Med Res Opin. 2020;36(5):713–30.
pubmed: 32050807
doi: 10.1080/03007995.2020.1729708
Liberman JN, Lichtenfeld MJ, Galaznik A, Mastey V, Harnett J, Zou KH, et al. Adherence to varenicline and associated smoking cessation in a community-based patient setting. J Manag Care Pharm. 2013;19(2):125–31.
pubmed: 23461428
Leung LK, Patafio FM, Rosser WW. Gastrointestinal adverse effects of varenicline at maintenance dose: A meta-analysis. BMC Clin Pharmacol. 2011;11(1):15.
pubmed: 21955317
pmcid: 3192741
doi: 10.1186/1472-6904-11-15
Thomas KH, Martin RM, Knipe DW, Higgins JPT, Gunnell D. Risk of neuropsychiatric adverse events associated with varenicline: Systematic review and meta-analysis. BMJ (Online). 2015;350:7–9.
Hollands GJ, Naughton F, Farley A, Lindson N, Aveyard P. Interventions to increase adherence to medications for tobacco dependence. Cochrane Database Syst Rev. 2019;8:CD009164.
pubmed: 31425618
Mooney M, Babb D, Jensen J, Hatsukami D. Interventions to increase use of nicotine gum: a randomized, controlled, single-blind trial. Nicotine Tob Res. 2005;7(4):565–79.
pubmed: 16085528
doi: 10.1080/14622200500185637
Mooney ME, Sayre SL, Hokanson PS, Stotts AL, Schmitz JM. Adding MEMS feedback to behavioral smoking cessation therapy increases compliance with bupropion: a replication and extension study. Addict Behav. 2007;32(4):875–80.
pubmed: 16839698
doi: 10.1016/j.addbeh.2006.06.022
Nollen NL, Cox LS, Nazir N, Ellerbeck EF, Owen A, Pankey S, et al. A pilot clinical trial of varenicline for smoking cessation in black smokers. Nicotine Tob Res. 2011;13(9):868–73.
pubmed: 21498427
pmcid: 3203399
doi: 10.1093/ntr/ntr063
Tucker JS, Shadel WG, Galvan FH, Naranjo D, Lopez C, Setodji C. Pilot evaluation of a brief intervention to improve nicotine patch adherence among smokers living with HIV/AIDS. Psychol Addict Behav. 2017;31(2):148–53.
pubmed: 27736144
doi: 10.1037/adb0000221
Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, et al. A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance. BMJ. 2021;374:n2061. https://doi.org/10.1136/bmj.n2061 .
Michie S. ABC of behaviour change theories. Silverback Publishing; 2014. Available from: https://cir.nii.ac.jp/crid/1130282273236722816 Cited 2023 Dec 22
Michie S, Richardson M, Johnston M, Abraham C, Francis J, Hardeman W, et al. The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: Building an international consensus for the reporting of behavior change interventions. Ann Behav Med. 2013;46(1):81–95.
pubmed: 23512568
doi: 10.1007/s12160-013-9486-6
Cane J, Richardson M, Johnston M, Ladha R, Michie S. From lists of behaviour change techniques (BCTs) to structured hierarchies: Comparison of two methods of developing a hierarchy of BCTs. Br J Health Psychol. 2015;20(1):130–50.
pubmed: 24815766
doi: 10.1111/bjhp.12102
Cane J, O’Connor D, Michie S. Validation of the theoretical domains framework for use in behaviour change and implementation research. Implement Sci. 2012;7(1):1–17.
doi: 10.1186/1748-5908-7-37
Michie S, van Stralen MM, West R. The behaviour change wheel: A new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6(1):42.
pubmed: 21513547
pmcid: 3096582
doi: 10.1186/1748-5908-6-42
Moons P, Goossens E, Thompson DR. Rapid reviews: the pros and cons of an accelerated review process. Eur J Cardiovasc Nurs. 2021;20(5):515–9.
pubmed: 34007994
doi: 10.1093/eurjcn/zvab041
Garritty C, Gartlehner G, Nussbaumer-Streit B, King VJ, Hamel C, Kamel C, et al. Cochrane Rapid Reviews Methods Group offers evidence-informed guidance to conduct rapid reviews. J Clin Epidemiol. 2021;130:13–22.
pubmed: 33068715
doi: 10.1016/j.jclinepi.2020.10.007
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;29:372.
Wirta D, Vollmer P, Paauw J, Chiu KH, Henry E, Striffler K, et al. Efficacy and safety of OC-01 (Varenicline Solution) nasal spray on signs and symptoms of Dry Eye Disease: The ONSET-2 Phase 3 Randomized Trial. Ophthalmology. 2022;129(4):379–87.
pubmed: 34767866
doi: 10.1016/j.ophtha.2021.11.004
McGill University Health Centre (MUHC) Libraries. 2019. Excluding Animal Studies. https://www.muhclibraries.ca/training-and-guides/excluding-animal-studies/ Cited 2022 Dec 30
Drug Approval Package: Chantix (Varenicline) NDA #021928. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021928_s000_chantixtoc.cfm Cited 2022 Apr 12
The EndNote Team. EndNote. Philadelphia: Clarivate; 2013.
Covidence systematic review software. Melbourne: Veritas Health Innovation;
Cane J, O’Connor D, Michie S. Validation of the theoretical framework. Implement Sci. 2012;7:37.
pubmed: 22530986
pmcid: 3483008
doi: 10.1186/1748-5908-7-37
The Joanna Briggs Institute Critical Appraisal Tools. Available from: https://jbi.global/critical-appraisal-tools Cited 2022 Jun 25
Hong QN, Pluye P, Fàbregues S, Bartlett G, Boardman F, Cargo M, et al. Improving the content validity of the mixed methods appraisal tool: a modified e-Delphi study. J Clin Epidemiol. 2019;111:49-59.e1.
pubmed: 30905698
doi: 10.1016/j.jclinepi.2019.03.008
Struik L, Rodberg D, Sharma RH. The Behavior Change Techniques Used in Canadian Online Smoking Cessation Programs: Content Analysis. JMIR Mental Health. 2022;9(3):1–12.
doi: 10.2196/35234
Nha HONG Q, Fàbregues S, Bartlett G, Boardman F, Cargo M, Dagenais P, et al. The Mixed Methods Appraisal Tool (MMAT) version 2018 for information professionals and researchers.
Aubin HJ, Bobak A, Britton JR, Oncken C, Billing CBJ, Gong J, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax. 2008;63(8):717–24.
pubmed: 18263663
doi: 10.1136/thx.2007.090647
Bolliger CT, Issa JS, Posadas-Valay R, Safwat T, Abreu P, Correia EA, et al. Effects of varenicline in adult smokers: A multinational, 24-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2011;33(4):465–77.
pubmed: 21635992
doi: 10.1016/j.clinthera.2011.04.013
Carroll A.J., Veluz-Wilkins A.K., Blazekovic S., Kalhan R., Leone F.T., Wileyto E.P., et al. Cancer-related disease factors and smoking cessation treatment: Analysis of an ongoing clinical trial. Psycho-Oncology. 2017;((Carroll, Veluz-Wilkins, Kalhan, Hitsman) Northwestern University Feinberg School of Medicine Chicago, IL USA(Blazekovic, Leone, Wileyto, Schnoll) University of Pennsylvania Perelman School of Medicine Philadelphia, PA USA). http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1099-1611
Catz SL, Jack LM, McClure JB, Javitz HS, Deprey M, Zbikowski SM, et al. Adherence to varenicline in the COMPASS smoking cessation intervention trial. Nicotine Tob Res. 2011;13(5):361–8.
pubmed: 21350041
pmcid: 3082504
doi: 10.1093/ntr/ntr003
Crawford G, Weisbrot J, Bastian J, Flitter A, Jao NC, Carroll A, et al. Predictors of Varenicline Adherence among cancer patients treated for tobacco dependence and its association with smoking cessation. Nicotine Tob Res. 2019;21(8):1135–9.
pubmed: 29955828
doi: 10.1093/ntr/nty133
Ebbert J, Jimenez-Ruiz C, Dutro MP, Fisher M, Li J, Hays JT. Frequently reported adverse events with smoking cessation medications: post hoc analysis of a randomized trial. Mayo Clin Proc. 2021;96(7):1801–11.
pubmed: 34112520
doi: 10.1016/j.mayocp.2020.10.046
Eisenberg MJ, Windle SB, Roy N, Old W, Grondin FR, Bata I, et al. Varenicline for smoking cessation in hospitalized patients with acute coronary syndrome. Circulation. 2016;133(1):21–30.
pubmed: 26553744
doi: 10.1161/CIRCULATIONAHA.115.019634
Fagerstrom K, Gilljam H, Metcalfe M, Tonstad S, Messig M. Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial. BMJ. 2010;341:c6549.
pubmed: 21134997
pmcid: 2997603
doi: 10.1136/bmj.c6549
Fouz-Roson N, Montemayor-Rubio T, Almadana-Pacheco V, Montserrat-Garcia S, Gomez-Bastero AP, Romero-Munoz C, et al. Effect of 0.5 mg versus 1 mg varenicline for smoking cessation: a randomized controlled trial. Addiction. 2017;112(9):1610–9.
pubmed: 28449281
doi: 10.1111/add.13855
Gong J, Baker CL, Zou KH, Bruno M, Jumadilova Z, Lawrence D, et al. A pragmatic randomized trial comparing telephone-based enhanced pharmacy care and usual care to support smoking cessation. J Manag Care Spec Pharm. 2016;22(12):1417–25.
pubmed: 27882838
Gray KM, Rubinstein ML, Prochaska JJ, DuBrava SJ, Holstein AR, Samuels L, et al. High-dose and low-dose varenicline for smoking cessation in adolescents: a randomised, placebo-controlled trial. Lancet Child Adolesc Health. 2020;4(11):837–45.
pubmed: 32979939
doi: 10.1016/S2352-4642(20)30243-1
Halperin AC, McAfee TA, Jack LM, Catz SL, McClure JB, Deprey TM, et al. Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting. J Subst Abuse Treat. 2009;36(4):428–34.
pubmed: 19004600
doi: 10.1016/j.jsat.2008.09.001
Hays JT, Leischow SJ, Lawrence D, Lee TC. Adherence to treatment for tobacco dependence: association with smoking abstinence and predictors of adherence. Nicotine Tob Res. 2010;12(6):574–81.
pubmed: 20457644
doi: 10.1093/ntr/ntq047
Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an alpha4ß2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial [corrected] [published erratum appears in JAMA 2006 Sep 20;296(11):1355]. JAMA. 2006;296(1):56–63.
pubmed: 16820547
doi: 10.1001/jama.296.1.56
Meszaros ZS, Abdul-Malak Y, Dimmock JA, Wang D, Ajagbe TO, Batki SL. Varenicline treatment of concurrent alcohol and nicotine dependence in schizophrenia: A randomized, placebo-controlled pilot trial. J Clin Psychopharmacol. 2013;33(2):243–7.
pubmed: 23422399
doi: 10.1097/JCP.0b013e3182870551
Nahvi S, Adams TR, Ning Y, Zhang C, Arnsten JH. Effect of varenicline directly observed therapy versus varenicline self-administered therapy on varenicline adherence and smoking cessation in methadone-maintained smokers: a randomized controlled trial. Addiction. 2021;116(4):902–13.
pubmed: 32857445
doi: 10.1111/add.15240
Nakamura M, Abe M, Ohkura M, Treadow J, Yu C-R, Park PW. Efficacy of Varenicline for cigarette reduction before quitting in Japanese smokers: a subpopulation analysis of the reduce to quit trial. Clin Ther. 2017;39(4):863–72.
pubmed: 28365035
doi: 10.1016/j.clinthera.2017.03.007
Niaura R, Hays JT, Jorenby DE, Leone FT, Pappas JE, Reeves KR, et al. The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. Curr Med Res Opin. 2008;24(7):1931–41.
pubmed: 18513462
doi: 10.1185/03007990802177523
Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med. 2006;166(15):1561–8.
pubmed: 16908788
doi: 10.1001/archinte.166.15.1561
Nides M, Glover ED, Reus VI, Christen AG, Make BJ, Billing CBJR, et al. Varenicline versus bupropion SR or placebo for smoking cessation A pooled analysis. Am J Health Behav. 2008;32(6):664–75.
pubmed: 18442345
doi: 10.5993/AJHB.32.6.10
Peng AR, Morales M, Wileyto EP, Hawk LWJ, Cinciripini P, George TP, et al. Measures and predictors of varenicline adherence in the treatment of nicotine dependence. Addict Behav. 2017;75:122–9 (2gw, 7603486).
pubmed: 28728040
pmcid: 5581992
doi: 10.1016/j.addbeh.2017.07.006
Peng AR, Swardfager W, Benowitz NL, Ahluwalia JS, Lerman C, Nollen NL, et al. Impact of early nausea on varenicline adherence and smoking cessation. Addiction. 2020;115(1):134–44.
pubmed: 31502736
doi: 10.1111/add.14810
Quinn MH, Bauer AM, Flitter A, Lubitz SF, Ashare RL, Thompson M, et al. Correlates of varenicline adherence among smokers with HIV and its association with smoking cessation. Addict Behav. 2020;102:106151 (2gw, 7603486).
pubmed: 31783245
doi: 10.1016/j.addbeh.2019.106151
Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation. 2010;121(2):221–9.
pubmed: 20048210
pmcid: 4096941
doi: 10.1161/CIRCULATIONAHA.109.869008
Rohsenow DJ, Tidey JW, Martin RA, Colby SM, Swift RM, Leggio L, et al. Varenicline versus nicotine patch with brief advice for smokers with substance use disorders with or without depression: effects on smoking, substance use and depressive symptoms. Addiction (Abingdon, England). 2017;112(10):1808–20.
pubmed: 28498504
doi: 10.1111/add.13861
Scoville EA, Tindle HA, Wells QS, Peyton SC, Gurwara S, Pointer SO, et al. Precision nicotine metabolism-informed care for smoking cessation in Crohn’s disease: A pilot study. PLoS ONE. 2020;15(3):e0230656.
pubmed: 32214373
pmcid: 7098646
doi: 10.1371/journal.pone.0230656
Shelley D, Tseng TY, Gonzalez M, Krebs P, Wong S, Furberg R, et al. Correlates of Adherence to Varenicline Among HIV+ Smokers. Nicotine Tob Res. 2015;17(8):968–74.
pubmed: 26180221
pmcid: 4580547
doi: 10.1093/ntr/ntv068
Stein MD, Caviness CM, Kurth ME, Audet D, Olson J, Anderson BJ. Varenicline for smoking cessation among methadone-maintained smokers: a randomized clinical trial. Drug Alcohol Depend. 2013;133(2):486–93.
pubmed: 23953658
doi: 10.1016/j.drugalcdep.2013.07.005
Swan GE, Javitz HS, Jack LM, Wessel J, Michel M, Hinds DA, et al. Varenicline for smoking cessation: Nausea severity and variation in nicotinic receptor genes. Pharmacogenomics J. 2012;12(4):349–58.
pubmed: 21606948
doi: 10.1038/tpj.2011.19
Tashkin DP, Rennard S, Hays JT, Ma W, Lawrence D, Lee TC. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: A randomized controlled trial. Chest. 2011;139(3):591–9.
pubmed: 20864613
doi: 10.1378/chest.10-0865
Tonstad S. Smoking cessation efficacy and safety of varenicline, an alpha4ß2 nicotinic receptor partial agonist. J Cardiovasc Nurs. 2006;21(6):433–6.
pubmed: 17293731
doi: 10.1097/00005082-200611000-00004
Tonstad S, Tønnesen P, Hajek P, Williams KE, Billing CB, Reeves KR, et al. Effect of maintenance therapy with varenicline on smoking cessation a randomized controlled trial. JAMA. 2006;296(1):64–71.
pubmed: 16820548
doi: 10.1001/jama.296.1.64
Tonstad S, Lawrence D. Varenicline in smokers with diabetes: A pooled analysis of 15 randomized, placebo-controlled studies of varenicline. J Diabetes Investig. 2017;8(1):93–100.
pubmed: 27223809
doi: 10.1111/jdi.12543
Tsai ST, Cho HJ, Cheng HS, Kim CH, Hsueh KC, Billing CBJ, et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther. 2007;29(6):1027–39.
pubmed: 17692719
doi: 10.1016/j.clinthera.2007.06.011
Tseng TY, Krebs P, Schoenthaler A, Wong S, Sherman S, Gonzalez M, et al. Combining text messaging and telephone counseling to increase varenicline adherence and smoking abstinence among cigarette smokers living with HIV: a randomized controlled study. AIDS Behav. 2017;21(7):1964–74.
pubmed: 27605365
pmcid: 5554578
doi: 10.1007/s10461-016-1538-z
Tulloch HE, Pipe AL, Els C, Clyde MJ, Reid RD. Flexible, dual-form nicotine replacement therapy or varenicline in comparison with nicotine patch for smoking cessation: A randomized controlled trial. BMC Med. 2016;14(1):80.
pubmed: 27233840
pmcid: 4884360
doi: 10.1186/s12916-016-0626-2
Walker N, Smith B, Barnes J, Verbiest M, Parag V, Pokhrel S, et al. Cytisine versus varenicline for smoking cessation in New Zealand indigenous Māori: a randomized controlled trial. Addiction. 2021;116(10):2847.
pubmed: 33761149
pmcid: 8519028
doi: 10.1111/add.15489
Williams KE, Reeves KR, Billing CBJ, Pennington AM, Gong J. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin. 2007;23(4):793–801.
pubmed: 17407636
doi: 10.1185/030079907X182185
Boudrez H, Gratziou C, Messig M, Metcalfe M. Effectiveness of varenicline as an aid to smoking cessation: results of an inter-European observational study. Curr Med Res Opin. 2011;27(4):769–75.
pubmed: 21294601
doi: 10.1185/03007995.2011.557718
Chu S, Liang L, Jing H, Zhang D, Tong Z. Safety of varenicline as an aid to smoking cessation in professional drivers and its impact on driving behaviors: An observational cohort study of taxi drivers in Beijing. Tobacco Induced Diseases. 2020;18:120935 (Chu, Liang, Jing, Zhang) Department of Clinical Epidemiology and Tobacco Dependence Treatment Research, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China(Chu, Liang, Jing, Zhang, Tong) Beijing Institute of Respiratory Medicine, Beijin).
doi: 10.18332/tid/120935
Ebbert JO, Croghan IT, North F, Schroeder DR. A pilot study to assess smokeless tobacco use reduction with varenicline. Nicotine Tob Res. 2010;12(10):1037–40.
pubmed: 20724382
pmcid: 2948050
doi: 10.1093/ntr/ntq134
Grassi MC, Enea D, Ferketich AK, Lu B, Pasquariello S, Nencini P. Effectiveness of varenicline for smoking cessation: a 1-year follow-up study. J Subst Abuse Treat. 2011;41(1):64–70.
pubmed: 21349681
doi: 10.1016/j.jsat.2011.01.014
Harrison-Woolrych M, Ashton J. Utilization of the smoking cessation medicine varenicline: an intensive post-marketing study in New Zealand. Pharmacoepidemiol Drug Saf. 2010;19(9):949–53.
pubmed: 20602347
doi: 10.1002/pds.2003
Hernandez Zenteno RJ, Lara DF, Venegas AR, Sansores RH, Pineda JR, Trujillo FF, et al. Varenicline for long term smoking cessation in patients with COPD. Pulm Pharmacol Ther. 2018;53:116–20 (Hernandez Zenteno, Lara, Trujillo) COPD Clinic, National Institute of Respiratory Diseases, Calzada de Tlalpan 4502 Seccion XVI, Mexico City, PC 14080, Mexico(Venegas, Pineda, Perez Padilla) Department of Research in Tobacco Smoking and COPD, National In).
pubmed: 30399395
doi: 10.1016/j.pupt.2018.11.001
Hodgkin JE, Sachs DPL, Swan GE, Jack LM, Titus BL, Waldron SJS, et al. Outcomes from a patient-centered residential treatment plan for tobacco dependence. Mayo Clin Proc. 2013;88(9):970–6.
pubmed: 24001489
doi: 10.1016/j.mayocp.2013.05.027
Jimenez-Ruiz CA, Barrios M, Pena S, Cicero A, Mayayo M, Cristobal M, et al. Increasing the dose of varenicline in patients who do not respond to the standard dose. Mayo Clin Proc. 2013;88(12):1443–5.
pubmed: 24290118
doi: 10.1016/j.mayocp.2013.08.015
Jimenez-Ruiz CA, Garcia Rueda M, Martinez Muniz MA, Sellares J, Jimenez-Fuentes MA, Lazaro Asegurado L, et al. Varenicline in smokers with severe or very severe COPD after 24 weeks of treatment A descriptive analysis VALUE study. Monaldi Arch Chest Dis. 2017;87(3):874.
pubmed: 29424192
Jung JW, Jeon EJ, Kim JG, Yang SY, Choi JC, Shin JW, et al. Clinical experience of varenicline for smoking cessation. Clin Respir J. 2010;4(4):215–21.
pubmed: 20887344
doi: 10.1111/j.1752-699X.2009.00178.x
Ock M, Shin JS, Ra SW. Safety and Effectiveness of Varenicline in Korean Smokers: A Nationwide Post-Marketing Surveillance Study. Patient Prefer Adherence. 2022;16:413–26 ((Ock) Department of Preventive Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea(Shin) Medical Affairs, Pfizer Korea, Seoul, South Korea(Ra) Department of Internal Medicine, Ulsan University Hospital, Univers).
pubmed: 35210758
pmcid: 8858022
doi: 10.2147/PPA.S344757
Park PW, Casiano EM, Escoto L, Claveria AM. Observational study of safety and efficacy of varenicline for smoking cessation among Filipino smokers. Curr Med Res Opin. 2011;27(10):1869–75.
pubmed: 21838412
doi: 10.1185/03007995.2011.607436
Park ER, Japuntich S, Temel J, Lanuti M, Pandiscio J, Hilgenberg J, et al. A smoking cessation intervention for thoracic surgery and oncology clinics: a pilot trial. J Thor Oncol. 2011;6(6):1059–65.
doi: 10.1097/JTO.0b013e318215a4dc
Pozzi P, Munarini E, Bravi F, Rossi M, La Vecchia C, Boffi R, et al. A combined smoking cessation intervention within a lung cancer screening trial: A pilot observational study. Tumori. 2015;101(3):306–11.
pubmed: 25838249
doi: 10.5301/tj.5000282
Raich A, Ballbe M, Nieva G, Cano M, Fernandez T, Bruguera E, et al. Safety of varenicline for smoking cessation in psychiatric and addicts patients. Subst Use Misuse. 2016;51(5):649–57.
pubmed: 27050328
doi: 10.3109/10826084.2015.1133646
van Boven JFM, Vemer P. Higher adherence during reimbursement of pharmacological smoking cessation treatments. Nicotine Tob Res. 2016;18(1):56–63.
pubmed: 25782457
Wang C, Cho B, Xiao D, Wajsbrot D, Park PW. Effectiveness and safety of varenicline as an aid to smoking cessation: results of an inter-Asian observational study in real-world clinical practice. Int J Clin Pract. 2013;67(5):469–76.
pubmed: 23574106
doi: 10.1111/ijcp.12121
Balmford J, Borland R, Hammond D, Cummings KM. Adherence to and reasons for premature discontinuation from stop-smoking medications: data from the ITC Four-Country Survey. Nicotine Tob Res. 2011;13(2):94–102.
pubmed: 21147894
doi: 10.1093/ntr/ntq215
Etter JF, Schneider NG. An internet survey of use, opinions and preferences for smoking cessation medications: nicotine, varenicline, and bupropion. Nicotine Tob Res. 2013;15(1):59–68.
pubmed: 22529220
doi: 10.1093/ntr/nts084
Purvis TL, Mambourg SE, Balvanz TM, Magallon HE, Pham RH. Safety and effectiveness of varenicline in a veteran population with a high prevalence of mental illness. Ann Pharmacother. 2009;43(5):862–7.
pubmed: 19383936
doi: 10.1345/aph.1L661
Heydari G. Is cost of medication for quit smoking important for smokers, experience of using champix in Iranian smoking cessation program 2016. Int J Prev Med. 2017;8:63 ((Heydari) Tobacco Prevention and Control Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic of).
pubmed: 28966752
pmcid: 5609398
doi: 10.4103/ijpvm.IJPVM_375_16
Ramon JM, Bruguera E. Real world study to evaluate the effectiveness of varenicline and cognitive-behavioural interventions for smoking cessation. Int J Environ Res Public Health. 2009;6(4):1530–8.
pubmed: 19440532
pmcid: 2681200
doi: 10.3390/ijerph6041530
Skelton E, Lum A, Cooper LE, Barnett E, Smith J, Everson A, et al. Addressing smoking in sheltered homelessness with intensive smoking treatment (ASSIST project): A pilot feasibility study of varenicline, combination nicotine replacement therapy and motivational interviewing. Addict Behav. 2022;124:107074 (2gw, 7603486).
pubmed: 34509787
doi: 10.1016/j.addbeh.2021.107074
Gordon JS, Armin JS, Cunningham JK, Muramoto ML, Christiansen SM, Jacobs TA. Lessons learned in the development and evaluation of RxCoachTM, an mHealth app to increase tobacco cessation medication adherence. Patient Educ Couns. 2017;100(4):720–7.
pubmed: 27839891
doi: 10.1016/j.pec.2016.11.003
Atkins L, Francis J, Islam R, O’Connor D, Patey A, Ivers N, et al. A guide to using the Theoretical Domains Framework of behaviour change to investigate implementation problems. Implementation Sci. 2017;12(1):1–18.
doi: 10.1186/s13012-017-0605-9
Prajapati AR, Dima A, Mosa G, Scott S, Song F, Wilson J, et al. Mapping modifiable determinants of medication adherence in bipolar disorder (BD) to the theoretical domains framework (TDF): a systematic review. Psychol Med. 2021;51(7):1082–98.
pubmed: 34006337
pmcid: 8188530
doi: 10.1017/S0033291721001446
Mersha AG, Gould GS, Bovill M, Eftekhari P. Barriers and facilitators of adherence to nicotine replacement therapy: a systematic review and analysis using the capability, opportunity, motivation, and behaviour (COM-B) Model. Int J Environ Res Public Health. 2020;17(23):8895.
pubmed: 33265956
pmcid: 7731205
doi: 10.3390/ijerph17238895
Vallis M, Jin S, Klimek-Abercrombie A, Bunko A, Kukaswadia A, Neish CS, et al. Understanding strategies to improve medication adherence among persons with type 2 diabetes: A scoping review. Diabet Med. 2023;40(1): e14941.
pubmed: 35996880
doi: 10.1111/dme.14941
Crayton E, Fahey M, Ashworth M, Besser SJ, Weinman J, Wright AJ. Psychological determinants of medication adherence in stroke survivors: a systematic review of observational studies. Ann Behav Med. 2017;51(6):833–45.
pubmed: 28421453
doi: 10.1007/s12160-017-9906-0
Easthall C, Taylor N, Bhattacharya D. Barriers to medication adherence in patients prescribed medicines for the prevention of cardiovascular disease: a conceptual framework. Int J Pharm Pract. 2019;27(3):223–31.
pubmed: 30281179
doi: 10.1111/ijpp.12491
Rahman M, Judah G, Murphy D, Garfield SF. Which domains of the theoretical domains framework should be targeted in interventions to increase adherence to antihypertensives? Syst Rev J Hypertens. 2022;40(5):853–9.
doi: 10.1097/HJH.0000000000003113
Allemann SS, Nieuwlaat R, van den Bemt BJF, Hersberger KE, Arnet I. Matching adherence interventions to patient determinants using the Theoretical Domains Framework. Front Pharmacol. 2016;7:429.
pubmed: 27895583
pmcid: 5107738
doi: 10.3389/fphar.2016.00429
Adewuya AO, Afolabi MO, Ola BA, Ogundele OA, Ajibare AO, Oladipo BF, et al. The effect of psychological distress on medication adherence in persons with HIV infection in Nigeria. Psychosomatics. 2010;51(1):68–73.
pubmed: 20118443
doi: 10.1016/S0033-3182(10)70661-7
Milam JE, Richardson JL, Marks G, Kemper CA, Mccutchan AJ. The roles of dispositional optimism and pessimism in hiv disease progression. Psychol Health. 2004;19(2):167–81.
doi: 10.1080/08870440310001652696
Reach G, Benarbia L, Benhamou PY, Delemer B, Dubois S, Gouet D, et al. An unsafe/safe typology in people with type 2 diabetes: bridging patients’ expectations, personality traits, medication adherence, and clinical outcomes. Patient Prefer Adherence. 2022;16:1333–50.
pubmed: 35642243
pmcid: 9148599
doi: 10.2147/PPA.S365398
Kahwati L, Viswanathan M, Golin CE, Kane H, Lewis M, Jacobs S. Identifying configurations of behavior change techniques in effective medication adherence interventions: a qualitative comparative analysis. Syst Rev. 2016;5(1):83.
pubmed: 27209092
pmcid: 4875709
doi: 10.1186/s13643-016-0255-z
Armitage LC, Kassavou A, Sutton S. Do mobile device apps designed to support medication adherence demonstrate efficacy? A systematic review of randomised controlled trials, with meta-analysis. BMJ Open. 2020;10(1):e032045.
pubmed: 32005778
pmcid: 7045248
doi: 10.1136/bmjopen-2019-032045
Long H, Bartlett YK, Farmer AJ, French DP. Identifying brief message content for interventions delivered via mobile devices to improve medication adherence in people with type 2 Diabetes Mellitus: A Rapid Systematic Review. J Med Internet Res. 2019;21(1):e10421.
pubmed: 30626562
pmcid: 6329430
doi: 10.2196/10421
Minian N, Mehra K, Rose J, Veldhuizen S, Zawertailo L, Ratto M, et al. Cocreation of a conversational agent to help patients adhere to their varenicline treatment: A study protocol. DIGITAL HEALTH. 2023;1(9):20552076231182810.
doi: 10.1177/20552076231182807
Minian N, Mehra K, Earle M, Hafuth S, Ting-A-Kee R, Rose J, et al. AI conversational agent to improve Varenicline Adherence: protocol for a mixed methods feasibility study. JMIR Res Protoc. 2023;12(1):e53556.
pubmed: 38079201
pmcid: 10750231
doi: 10.2196/53556